|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma.
|
1681026 |
1991 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epstein-Barr virus (EBV) genome-positive nasopharyngeal carcinomas (NPCs) regularly express the virus-coded nuclear antigen EBNA1, but not other EBNAs, and a subset of tumors also appear to be latent membrane protein LMP1 positive; the status of NPCs with respect to a second virus-coded latent membrane protein LMP2 is unknown.
|
1313894 |
1992 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Balb/c 3T3 cells carrying this NPC-LMP gene showed a transformed cell morphology and were tumorigenic in nude mice.
|
1331932 |
1992 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that partial deletions of the LMP1 oncogene, associated with aggressive behavior in NPC CAO and NPC 1510, occur at a particular localization and confer a proliferative phenotype to lymphoid cells in HD.
|
8219183 |
1993 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A predominant strain marked by an XhoI restriction enzyme polymorphism (REP) within the LMP-1 gene has been identified in type 1 EBV in nasopharyngeal carcinoma (NPC) from Southern China.
|
7931159 |
1994 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We reported earlier that variable expression of the Epstein-Barr virus (EBV) encoded membrane protein LMP 1 in nasopharyngeal carcinoma and the host-cell-phenotype-dependent activity of the BCR2 promoter (one of the possible initiator sites for transcripts of Epstein-Barr nuclear antigens) in Burkitt's lymphoma (BL) lines can be related to the methylation status of the 5'-flanking regulatory regions of the BNLF 1 and BCR2 promoter, respectively.
|
8178450 |
1994 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A particular LMP1 deletion mutant was recently identified in NPC and clinically and histologically aggressive HD.
|
7885044 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although LMP1 is expressed in the majority of nasopharyngeal carcinoma (NPC) tumors, the effect of LMP1 on cellular gene expression and its contribution to the development of malignancy in epithelial cells is largely unknown.
|
7769701 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous in vitro studies have suggested that LMP1 expression might be a function of differentiation, but this study of naturally infected NPCs showed no strong correlation between LMP1 positivity and degree of tumor differentiation, albeit a limited spectrum of differentiation that could be examined.
|
7590694 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The complete 5' sequence of the Epstein-Barr virus 3.5-kb latent membrane protein 1 (LMP1) mRNA, expressed in nasopharyngeal carcinoma, has been determined.
|
7769727 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No correlation was found between the presence of EBER1-2 transcripts or LMP-1 protein and the beta 2-microglobulin-reduced expression in NPC.
|
8738471 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The detection of the EBV-transforming gene, LMP-1, in all the neoplastic cells suggests that its expression is essential for preinvasive epithelial proliferations associated with nasopharyngeal carcinoma.
|
7637746 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, expression of the late gene encoding the lytic truncated form of LMP1 (D1LMP) was found in seven of the eight NPC biopsies.
|
7782768 |
1995 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Xho-I site mutant of the LMP-1 gene previously characterized in Chinese NPC also prevailed in NPTL and IM with an identical nucleotide sequence.
|
8950688 |
1996 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LMP-1 is expressed in EBV-transformed lymphoblastoid cell lines, nasopharyngeal carcinoma (NPC), a subset of Hodgkin's disease (HD), and in EBV-associated lymphoproliferative disorders (EBV-LPDs).
|
8704180 |
1996 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis of the carboxy-terminal part of the LMP-1 gene revealed no deletions but seven single-base substitutions, four of which were found to be identical to those previously detected in codons for amino acids 322 to 366 in the Chinese NPC CAO.
|
8955472 |
1996 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The latent membrane protein 1 (LMP1) oncogene of Epstein Barr virus (EBV) is expressed in tumor cells of acquired immunodeficiency syndrome (AIDS) related lymphomas, HIV-negative, EBV-associated malignant lymphoproliferations, nasopharyngeal carcinoma, as well as in reactive immunoblasts of infectious mononucleosis.
|
9322886 |
1997 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP1 is present in the majority of nasopharyngeal carcinoma tumor cells and in Reed-Sternberg cells from Hodgkin's lymphoma, in which the only EBV nuclear antigen detected is EBNA1.
|
9406991 |
1997 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we reported that the LMP 1 gene of Epstein-Barr virus (EBV) derived from nasopharyngeal carcinoma (NPC) tissues (i.e., NLMP 1 gene) was able to transform BALB/c3T3 cells.
|
9407003 |
1997 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To test if the LMP 1 gene of the NPC strain also contained an upstream promoter, we generated a series of deletion plasmids encompassing positions -1,030 to +20 of the LMP 1 promoter and tested for their abilities to drive the expression of the reporter gene in human epithelial cell lines, C-33A and NPC-TW076.
|
9260926 |
1997 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Epstein-Barr Virus (EBV) LMP1 protein is frequently expressed in nasopharyngeal carcinoma and is essential for the transforming effects of EBV.
|
9583684 |
1998 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that 92% (34/37) of primary NPC tumours harboured EBV-1 and possessed the LMP1 deletion variant, of which 86% were Asp335 and 6% were Gly335.
|
9579578 |
1998 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 30-bp deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) gene has been reported in nasopharyngeal carcinoma and EBV-associated malignant lymphomas.
|
9422536 |
1998 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The transforming ability of the LMP1 gene with the insertion was greater than that of the other HD-derived LMP1, and was comparable with the highly transforming LMP1-Cao gene derived from a nasopharyngeal carcinoma.
|
9537580 |
1998 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, a 30-bp deletion is observed near the 3' end of the LMP1 gene in the majority of EBV (86%) from NPC and peripheral-blood cells from Asians, whereas a significantly lower percentage (p < 0.001) of NPC biopsies from European and North African patients (56%) have this deletion, as do lymphocytes from control individuals from the same region (36 and 55% respectively).
|
9466647 |
1998 |